Vigilancia de la pandemia de gripe (H1N1) 2009 en España

Larrauri, Amparo; Jiménez-Jorge, Silvia; Méndez, Lorena Simón; Ontañón, Salvador de Mateo

doi:10.1590/s1135-57272010000500009

Cited by 11 publications

(19 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first patient included in the study was recruited on August 1st. Peak activity was observed on week 46/2009 in both, Spanish surveillance system and our study [9].…”

Section: Resultssupporting

confidence: 64%

“…If we consider that 99.8% of clinical cases were outpatients, 0.15% were general-ward inpatients and 0.06% were ICU-inpatients, the mean cost per pandemic influenza A (H1N1) patient in Spain would be €954 [9], [10]. In the same country, Badia et al calculated the mean cost per patient with seasonal influenza-like illness to be €542.1 (95%CI = 487.1–597.1).…”

Section: Discussionmentioning

confidence: 99%

“…In addition, we estimated the economic burden of pandemic Influenza A (H1N1) at the overall population level from the healthcare provider's perspective. To achieve this objective we took into consideration both healthcare costs per patient and the reported number of influenza cases to the Spanish influenza Sentinel Surveillance System (outpatients) coordinated at the National Centre of Epidemiology (Institute of Health Carlos III) and to Surveillance System of severe influenza cases and deaths coordinated by the Centre for Health Alerts and Emergencies within Spanish Ministry of Health and Social Policy (inpatients) [9], [10].…”

Section: Methodsmentioning

confidence: 99%

“…At a national level, 852 and 2,173 inpatients with confirmed diagnosis of influenza were attended at ICU and general-ward, respectively [10]. Government institutions also estimated a total of 744,795 confirmed outpatients among the 1,414,000 estimated clinical cases [9]. We informed the economic impact on healthcare system for both, estimated confirmed and clinical cases.…”

Section: Methodsmentioning

confidence: 99%

“…Nevertheless, most flu cases will never be admitted to the hospital. For instance, 744,795 confirmed influenza A (H1N1) 2009 cases in Spain were treated in the ambulatory health services, and only 3,025 were hospitalized [9], [10].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Health Services Utilization, Work Absenteeism and Costs of Pandemic Influenza A (H1N1) 2009 in Spain: A Multicenter-Longitudinal Study

et al. 2012

View full text Add to dashboard Cite

BackgroundThe aim of this study was to estimate healthcare resource utilization, work absenteeism and cost per patient with pandemic influenza (H1N1)2009, from its beginning to March 2010, in Spain. We also estimated the economic impact on healthcare services.Methods and FindingsLongitudinal, descriptive, multicenter study of in- and outpatients with confirmed diagnosis of influenza A (H1N1) in Spain. Temporal distribution of cases was comparable to that in Spain. Information of healthcare and social resources used from one week before admission (inpatient) or index-medical visit (outpatient) until recovery was gathered. Unit cost was imputed to utilization frequency for the monetary valuation of use. Mean cost per patient was calculated. A sensitivity analysis was conducted, and variables correlated with cost per patient were identified. Economic impact on the healthcare system was estimated using healthcare costs per patient and both, the reported number of confirmed and clinical cases in Spain. 172 inpatients and 224 outpatients were included. Less than 10% were over 65 years old and more than 50% had previous comorbidities. 12.8% of inpatients were admitted to the Intensive Care Unit. Mean length of hospital stay of patients not requiring critical care was 5 days (SD = 4.4). All working-inpatients and 91.7% working-outpatients went on sick leave. On average, work absenteeism was 30.5 days (SD = 20.7) for the first ones and 9 days (SD = 6.3) for the latest. Caregivers of 21.7% of inpatients and 8.5% of outpatients also had work absenteeism during 10.7 and 4.1 days on average respectively. Mean cost was €6,236/inpatient (CI95% = 1,384–14,623) and €940/outpatient (CI95% = 66–3,064). The healthcare economic burden of patients with confirmed influenza was €144,773,577 (IC95% 13,753,043–383,467,535). More than 86% of expenditures were a result of outpatients' utilization.ConclusionCost per H1N1-patient did not defer much from seasonal influenza estimates. Hospitalizations and work absenteeism represented the highest cost per patient.

show abstract

“…The first patient included in the study was recruited on August 1st. Peak activity was observed on week 46/2009 in both, Spanish surveillance system and our study [9].…”

Section: Resultssupporting

confidence: 64%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Health Services Utilization, Work Absenteeism and Costs of Pandemic Influenza A (H1N1) 2009 in Spain: A Multicenter-Longitudinal Study

et al. 2012

View full text Add to dashboard Cite

show abstract

Nucleic acid-based therapy for coronavirus disease 2019

Piyush¹,

Rajarshi²,

Chatterjee³

et al. 2020

Heliyon

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19), the pandemic that originated in China has already spread into more than 190 countries, resulting in huge loss of human life and many more are at the stake of losing it; if not intervened with the best therapeutics to contain the disease. For that aspect, various scientific groups are continuously involved in the development of an effective line of treatment to control the novel coronavirus from spreading rapidly. Worldwide scientists are evaluating various biomolecules and synthetic inhibitors against COVID-19; where the nucleic acid-based molecules may be considered as potential drug candidates. These molecules have been proved potentially effective against SARS-CoV, which shares high sequence similarity with SARS-CoV-2. Recent advancements in nucleic acid-based therapeutics are helpful in targeted drug delivery, safely and effectively. The use of nucleic acid-based molecules also known to regulate the level of gene expression inside the target cells. This review mainly focuses on various nucleic acid-based biologically active molecules and their therapeutic potentials in developing vaccines for SARS-CoV-2.

show abstract